Company / Operating Cash Flow
Solid Biosciences Inc. Operating Cash Flow History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$56.6M
FY2022
5-year range
-$92.7M / -$20.1M
FY2018-FY2022
Trend
+39.0%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2022 after 3 years of decline, reaching -$57M.
Based on SEC 10-K filings.
-$57M in FY2022.
Improved from -$70M to -$57M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, operating cash flow increased 39.0% year-over-year.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$56.6M | +39.0% |
| FY2021 | -$92.7M | -32.1% |
| FY2020 | -$70.2M | -62.4% |
| FY2019 | -$43.2M | -114.8% |
| FY2018 | -$20.1M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026